Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
Status:
Terminated
Trial end date:
2017-04-28
Target enrollment:
Participant gender:
Summary
Standard treatment for AL Amyloidosis is high-dose melphalan and stem cell transplant.
This study will compare the safety and effectiveness of standard treatment with high-dose
melphalan and stem cell transplant, compared with investigational bortezomib when used in
combination with standard treatment with high-dose melphalan and stem cell transplant for AL
amyloidosis.